Has Michael Cohen, MD received payments from drug or device companies?

Yes. Drug and device makers reported $412 in general payments to Michael Cohen, MD across 40 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Michael Cohen, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Michael Cohen, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Michael Cohen, MD

Nephrology · Reading, MANPI 1306895172

Payments from drug & device makers

$412in general payments, 2019–2025

Across 40 payments — averaging $10.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Travere Therapeutics, Inc.$226
Novo Nordisk$49
AstraZeneca$45
Vifor Pharma, Inc.$27
Otsuka America Pharmaceutical, Inc.$25
Ardelyx, Inc.$24
plus $16 from 1 others

What the payments were for

Food & beverage$24660%
Education$16640%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Travere Therapeutics, Inc.	32	$226
Novo Nordisk	2	$49
AstraZeneca	2	$45
Vifor Pharma, Inc.	1	$27
Otsuka America Pharmaceutical, Inc.	1	$25
Ardelyx, Inc.	1	$24
Amgen	1	$16

How this compares

$412 in reported general payments places this provider in the 50th percentile of 339 nephrology providers in Massachusetts.

See all nephrology providers in Massachusetts →

Medicare billing

Part B allowed, 2024

$252,728

Medicare patients

527

Services billed

1,423

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
VelphoroSucroferric Oxyhydroxide	22	$68,392
JardianceEmpagliflozin	27	$42,688
LokelmaSodium Zirconium Cyclosilicate	24	$28,935
FarxigaDapagliflozin Propanediol	12	$18,041
Sevelamer Carbonate	34	$7,533
Torsemide	49	$2,285
Amlodipine Besylate	151	$1,492
Lisinopril	133	$1,184
Doxazosin Mesylate	59	$1,142
Calcitriol	40	$994
Calcium Acetate	15	$972
Sodium Polystyrene Sulfonate	11	$720
Furosemide	63	$656
Labetalol Hcl	17	$606
Losartan Potassium	52	$524

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AstraZenecaLokelma, Farxiga	$45	$46,97536 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 339 nephrology providers in Massachusetts.